IN2014MN02175A - - Google Patents
Info
- Publication number
- IN2014MN02175A IN2014MN02175A IN2175MUN2014A IN2014MN02175A IN 2014MN02175 A IN2014MN02175 A IN 2014MN02175A IN 2175MUN2014 A IN2175MUN2014 A IN 2175MUN2014A IN 2014MN02175 A IN2014MN02175 A IN 2014MN02175A
- Authority
- IN
- India
- Prior art keywords
- nme
- coh
- double bond
- independently
- single bond
- Prior art date
Links
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101710134866 Quinone reductase Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
2 2227231 73 20 5 201011Q Q1 7x11 2 2121m13 20 41 42n3 202n3 20112211 4 A compound of formula (I) or a salt or solvate thereof wherein the dotted double bond indicates the presence of a single or double bond between C2 and C3; Ris selected from H OH =O =CH CN R OR halo dihalo =CHR =CHRR O SO R COR and COR; R is selected from H R OH OR SH SR NH NHR NRR nitro MeSn and halo; where R and R are independently selected from optionally substituted C alkyl Cheterocyclyl and C aryl groups; R and R either together form a double bond or are selected from H and QRrespectively where Q is selected from O S and NH and R is H or C alkyl or H and SOM where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; A is selected from (A1) (A2) (A3) (A4) or (A5) where X and Yare selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O respectively; Xand Y are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O respectively; Z is selected from O and S; Z is selected from CH and N; F is selected from a single bond and (E F) ; each E is independently selected from a single bond and C(=O) NH ; each F is independently a C heteroarylene group; m is 1 2 or 3; G is selected from hydrogen C1alkyl C(=O) O Calkyl (CH) C heterocycloalkyl and O (CH) C heterocycloalkyl group; each n is 0 4; provided that A2 is not A2 where X and Y of A2 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S respectively; and provided that A3 is not A3 where X and Y of A3 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S respectively; B is either a single bond or (B1) where X and Y of B1 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S respectively; and R is Calkyl.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640316P | 2012-04-30 | 2012-04-30 | |
| PCT/GB2013/051097 WO2013164592A1 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02175A true IN2014MN02175A (en) | 2015-08-28 |
Family
ID=48289484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2175MUN2014 IN2014MN02175A (en) | 2012-04-30 | 2013-04-30 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9321774B2 (en) |
| EP (1) | EP2855481A1 (en) |
| JP (1) | JP6125614B2 (en) |
| KR (1) | KR101960130B1 (en) |
| CN (1) | CN104540827B (en) |
| AU (1) | AU2013255612B2 (en) |
| BR (1) | BR112014027190B1 (en) |
| CA (1) | CA2872205C (en) |
| HK (1) | HK1208217A1 (en) |
| IN (1) | IN2014MN02175A (en) |
| MX (1) | MX2014013144A (en) |
| NZ (1) | NZ701478A (en) |
| WO (1) | WO2013164592A1 (en) |
| ZA (1) | ZA201408043B (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
| JP5870400B2 (en) | 2010-04-15 | 2016-03-01 | シアトル ジェネティクス，インコーポレーテッド | Targeted pyrrolobenzodiazepine conjugates |
| WO2013041606A1 (en) | 2011-09-20 | 2013-03-28 | Spirogen Sàrl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| JP6393617B2 (en) | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス，インコーポレーテッド | Pyrrolobenzodiazepine and target conjugates |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013053871A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| JP5993093B2 (en) | 2012-10-12 | 2016-09-14 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | Pyrrolobenzodiazepines and their complexes |
| DK2906248T3 (en) | 2012-10-12 | 2019-03-04 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| HK1216176A1 (en) | 2012-12-21 | 2016-10-21 | Medlmmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014229529B2 (en) | 2013-03-13 | 2018-02-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| BR112017011111A2 (en) | 2014-11-25 | 2017-12-26 | Adc Therapeutics Sa | pyrrolobenzodiazepine-antibody conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201521709D0 (en) * | 2015-12-09 | 2016-01-20 | Kings College London And Sec Dep For Health The | PBD Antibacterial agents |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017201132A2 (en) | 2016-05-18 | 2017-11-23 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| WO2017223275A1 (en) * | 2016-06-24 | 2017-12-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| HUE054689T2 (en) | 2017-02-08 | 2021-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| SI3612537T1 (en) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
| CA3064804A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| TWI885539B (en) | 2017-09-29 | 2025-06-01 | 日商第一三共股份有限公司 | Antibody-pyrrolobenzodiazepine derivative complex |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201900929D0 (en) * | 2019-01-23 | 2019-03-13 | King S College London | Nf-kappa b inhibitors |
| MX2021010477A (en) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer. |
| BR112022013008A2 (en) | 2019-12-31 | 2022-09-06 | Legochem Biosciences Inc | PYRROLOBENZODIAZEPINE DERIVATIVE COMPOUND, PYRROLOBENZODIAZEPINE BINDING DERIVATIVE CONJUGATE, AND, PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION OR TREATMENT OF PROLIFERATIVE DISEASE |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| US20250367307A1 (en) | 2022-06-30 | 2025-12-04 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| AU2023393382A1 (en) | 2022-12-14 | 2025-06-19 | Pheon Therapeutics Ltd | Cytotoxic compounds |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5569587A (en) | 1978-11-17 | 1980-05-26 | Meiji Seika Kaisha Ltd | Novel antibiotic neothramycin derivative and its preparation |
| JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
| JPS58180487A (en) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | Antibiotic dc-81 and its preparation |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| AU6645998A (en) | 1996-12-23 | 1998-07-17 | Du Pont Pharmaceuticals Company | Oxygen or sulfur containing heteroaromatics as factor xa inhibitors |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| DE69907977T2 (en) | 1998-08-27 | 2004-07-22 | Spirogen Ltd., Ryde | Pyrrolobenzodiazepine |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| DE60032022T2 (en) | 1999-12-20 | 2007-05-16 | The University Of North Carolina At Chapel Hill | DIAMIDINE COMPOUNDS AS DNA NON-BILATIN BINDER |
| AU2002251684A1 (en) * | 2000-12-27 | 2002-08-19 | Genelab Technologies, Inc. | Polyamide analogs as dna minor groove binders |
| CA2450625A1 (en) * | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| JP2005502703A (en) * | 2001-09-07 | 2005-01-27 | ザ スクリプス リサーチ インスティテュート | CC-1065 and CBI analogs of duocarmycin |
| US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| WO2005032594A2 (en) * | 2003-10-03 | 2005-04-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alkylators linked to polyamides as dna binding agents |
| GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP1720881B9 (en) | 2004-03-01 | 2013-04-17 | Spirogen Sàrl | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
| US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| EP1879901B1 (en) | 2005-04-21 | 2009-12-23 | Spirogen Limited | Pyrrolobenzodiazepines |
| WO2007039752A1 (en) * | 2005-10-05 | 2007-04-12 | Spirogen Limited | Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| US8406170B2 (en) | 2006-11-16 | 2013-03-26 | Telefonaktiebolaget Lm Ericsson (Publ) | Gateway selection mechanism |
| GB0722088D0 (en) * | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
-
2013
- 2013-04-30 IN IN2175MUN2014 patent/IN2014MN02175A/en unknown
- 2013-04-30 CN CN201380035161.8A patent/CN104540827B/en not_active Expired - Fee Related
- 2013-04-30 AU AU2013255612A patent/AU2013255612B2/en not_active Ceased
- 2013-04-30 JP JP2015509487A patent/JP6125614B2/en active Active
- 2013-04-30 BR BR112014027190-9A patent/BR112014027190B1/en not_active IP Right Cessation
- 2013-04-30 EP EP13720502.7A patent/EP2855481A1/en not_active Withdrawn
- 2013-04-30 NZ NZ701478A patent/NZ701478A/en not_active IP Right Cessation
- 2013-04-30 CA CA2872205A patent/CA2872205C/en not_active Expired - Fee Related
- 2013-04-30 HK HK15108789.1A patent/HK1208217A1/en unknown
- 2013-04-30 US US14/397,843 patent/US9321774B2/en not_active Expired - Fee Related
- 2013-04-30 MX MX2014013144A patent/MX2014013144A/en unknown
- 2013-04-30 WO PCT/GB2013/051097 patent/WO2013164592A1/en not_active Ceased
- 2013-04-30 KR KR1020147032596A patent/KR101960130B1/en not_active Expired - Fee Related
-
2014
- 2014-11-04 ZA ZA2014/08043A patent/ZA201408043B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1208217A1 (en) | 2016-02-26 |
| EP2855481A1 (en) | 2015-04-08 |
| KR101960130B1 (en) | 2019-03-19 |
| CN104540827B (en) | 2018-03-23 |
| JP6125614B2 (en) | 2017-05-10 |
| MX2014013144A (en) | 2015-05-11 |
| CN104540827A (en) | 2015-04-22 |
| BR112014027190A2 (en) | 2017-06-27 |
| AU2013255612B2 (en) | 2017-06-22 |
| BR112014027190B1 (en) | 2020-03-03 |
| ZA201408043B (en) | 2017-08-30 |
| US9321774B2 (en) | 2016-04-26 |
| KR20150014935A (en) | 2015-02-09 |
| AU2013255612A1 (en) | 2014-11-20 |
| CA2872205C (en) | 2020-07-21 |
| US20150126495A1 (en) | 2015-05-07 |
| CA2872205A1 (en) | 2013-11-07 |
| NZ701478A (en) | 2016-08-26 |
| WO2013164592A1 (en) | 2013-11-07 |
| JP2015516987A (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02175A (en) | ||
| BR112014027143A2 (en) | pyrrolobenzodiazepines | |
| EA201692215A1 (en) | Pyrrolbenzodiazepine and conjugates of directed action | |
| MY169495A (en) | Pharmaceutical compositions | |
| MX2015012629A (en) | Imidazo pyridine compounds. | |
| MX2013011257A (en) | Process for preparation of dronedarone by n-butylation. | |
| WO2013152277A3 (en) | Moenomycin analogs, methods of synthesis, and uses thereof | |
| MX352607B (en) | Process for preparing benzoxaboroles. | |
| MX395406B (en) | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTIPROLIFERATIVE ACTIVITY. | |
| IN2014DN07509A (en) | ||
| MX2014004144A (en) | Ethynyl derivatives as mglur5 allosteric modulators. | |
| WO2012103071A3 (en) | Compounds and compositions | |
| WO2013098836A8 (en) | A bis-quinophthalone pigment and a process for preparing the same | |
| MX377644B (en) | Steroid 6.7.beta.-epoxides as chemical intermediates | |
| MX2017017022A (en) | Method for the synthesis of rapamycin derivatives. | |
| EP4001266A3 (en) | Process for preparing methoxy methyl pyridine dicarboxylate | |
| GEAP202215389A (en) | Polymorphs | |
| MA39715A (en) | Polymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use | |
| MX2011006095A (en) | Dihydroetorphines and their preparation. | |
| MX346980B (en) | New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds. | |
| PH12015501215A1 (en) | Novel selective androgen receptor modulators | |
| MY185971A (en) | Pyranodipyridine compound | |
| MX359069B (en) | Salt and crystal forms of plk-4 inhibitor. | |
| IN2014MN00411A (en) | ||
| MX369470B (en) | Means and method for treating solid tumours. |